FDA Inspection
Baxter Oncology GmbHBaxter Oncology GmbH – FDA Inspection, May 3, 2023
Record Details
This FDA Inspection record concerns Baxter Oncology GmbH, with an inspection on May 3, 2023, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 49ff9f86-3d55-44a7-abeb-1a0511f483b6
Inspection Facts
No Action Indicated (NAI)
No objectionable conditions or practices were found during the inspection.
- Inspection number
- 1206312
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of Baxter Oncology GmbH
11| Date | Classification | Office | Project area |
|---|---|---|---|
| September 26, 2025 | OAI | Office of Inspections and Investigations | Drug Quality Assurance |
| August 27, 2024 | Not classified | Office of Inspections and Investigations | |
| January 29, 2020 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 3, 2019 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 14, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Baxter Oncology GmbH
- FDA Inspection 1283802 - 2025-09-26
- FDA Inspection 1249702 - 2024-08-27
- FDA Inspection 1161093 - 2020-01-29
- FDA Inspection 1106642 - 2019-09-03
- FDA Inspection 1056958 - 2018-06-14
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.